Abbott's XIENCE V(R) Approved in Japan - Second Largest Drug Eluting Stent Market Worldwide
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. Japan is the second largest drug eluting stent market in the world after the United States, with approximately 200,000 stent procedures performed each year.
AstraZeneca Reaches Agreements With Teva Pharmaceuticals
- Details
- Category: AstraZeneca
AstraZeneca has entered into an agreement with Teva Pharmaceutical Industries Ltd. and affiliates (collectively "Teva") to settle patent litigation regarding Teva's proposed generic version of AstraZeneca's Nexium delayed-release capsules (esomeprazole magnesium).
Pfizer and Strides Arcolab to Collaborate on Generic Products
- Details
- Category: Pfizer
Pfizer (NYSE: PFE) and Strides Arcolab (BSE: 532531, NSE: STAR) announced a new collaboration, wherein Pfizer will commercialize off-patent sterile injectable and oral products in the United States through its Established Products Business Unit. These finished dosage form products will be licensed and supplied by Strides and Onco Laboratories Limited and Onco Therapies Limited, two joint ventures between Strides and Aspen, South Africa, in which each has a 50% ownership interest.
Luitpold Pharmaceuticals, Inc. Acquires PharmaForce, Inc.
- Details
- Category: Business
Luitpold Pharmaceuticals, Inc., a New York based U.S. Company of Daiichi Sankyo Co., Ltd. (Corporate Headquarters: Tokyo, Japan) and PharmaForce, Inc., (Columbus, Ohio, USA), a privately-held fullyintegrated specialty injectable pharmaceutical company, announced today that PharmaForce has been acquired by Luitpold.
All three Novartis A(H1N1) 2009 influenza vaccines prequalified by World Health Organization
- Details
- Category: Novartis
Novartis announced that the World Health Organization (WHO) has granted prequalification for all three of its influenza A(H1N1) 2009 monovalent vaccines for supply to United Nations (UN) agencies: the cell culture-based and MF59® adjuvanted vaccine Celtura®, the egg-based and MF59 adjuvanted vaccine Focetria® as well as the egg-based A(H1N1) vaccine manufactured using the seasonal Fluvirin® platform.
Pfizer Provides U.S. Regulatory Update On Prevnar 13™ Vaccine
- Details
- Category: Pfizer
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13™, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company's candidate 13-valent pneumococcal conjugate vaccine.
Sanofi-aventis to Acquire Chattem Inc. Creating a Strong U.S. Consumer Healthcare Platform
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Chattem, Inc. (NASDAQ: CHTT) have entered into a definitive agreement under which sanofi-aventis is to acquire 100 percent of the outstanding shares of Chattem in a cash tender offer for $93.50 per share, or approximately $1.9 billion.
More Pharma News ...
- FDA Approves SPIRIVA® HandiHaler® for the Reduction of COPD Exacerbations
- Sanofi Pasteur to Develop & Commercialize Vaccine to Prevent Staphylococcus infections
- GSK publishes speaking, consulting fees paid to US healthcare professionals
- Array BioPharma and Amgen Partner in Type 2 Diabetes
- Takeda and Pfizer to Co-Promote Takeda's Actos® for the Treatment of Type 2 Diabetes in China
- Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems
- GSK and Intercell form strategic alliance to develop and commercialise innovative vaccines